Navigation Links
Two chemicals boost immune cells' ability to fight HIV without gene therapy

A UCLA AIDS Institute study has discovered that two chemical compounds may help the immune systems of HIV-infected persons fight the disease without invasive gene therapy. Presented March 5 at the 2005 Palm Springs Symposium on HIV/AIDS, the new research demonstrates that the new chemicals activate telomerase -- a protein that boosts immune cells' ability to divide, enabling them to continue destroying HIV-infected cells.

"The immune cells that fight HIV naturally produce telomerase during the infection's early phase, but stop once HIV becomes a chronic condition," explained Rita Effros, Ph.D., Plott Endowed Chair in Gerontology and a professor of pathology at the David Geffen School of Medicine at UCLA. "The two compounds switched telomerase back on in the cells."

In earlier research, the UCLA team showed that inserting the telomerase gene into the immune cells of an HIV-infected person prevented the cells from aging prematurely. The telomerase enabled the immune cells to divide indefinitely, stimulated their production of a viral-fighting molecule and prolonged their power to kill HIV-infected cells.

In this study, the scientists isolated immune cells from the blood of HIV-infected persons and cultured the cells with the chemical compounds. They were surprised to see that the compounds produced the same three changes in the cells as those created by the gene therapy.

"Lo and behold, we discovered we didn't need to use gene therapy to reactivate the telomerase and strengthen the immune system's capacity to stave off HIV," said Effros, a member of the UCLA AIDS Institute. "We were thrilled to see we could create the same changes in the cells without relying on an invasive procedure."

Immune cells that battle HIV must constantly divide in order to continue performing their protective functions. The massive amount of division prematurely shortens these cells' ends, or telomeres, ultimately exhausting the immune system.

UC LA's previous research shows that telomerase rejuvenates the telomeres and allows the immune cells to remain youthful and active as they replicate under HIV's attack. Drugs that activate telomerase also offer therapeutic potential for a wide spectrum of degenerative diseases and chronic conditions in which cellular aging plays a role.

"I'm really excited by our findings. This progress moves us one step closer to drugs that work by switching telomerase on permanently and keeping the immune cells young and strong in their fight against infection," said Effros. "These therapies are also easier to develop than gene-therapy drugs."

The research was supported by a grant from the National Institute of Allergy and Infectious Diseases and a University of California Discovery Grant. Geron provided additional funding and the chemical compounds for use in the laboratory.

Effros' team included doctoral student Steven Fauce; Beth Jamieson, Ph.D., assistant professor hematology-oncology; and Otto Yang, Ph.D., associate professor of infectious diseases, all from UCLA.


'"/>

Source:UCLA


Related biology news :

1. Harmful chemicals may reprogram gene response to estrogen
2. Pittsburgh researchers discover that certain chemicals in the blood may indicate brain injury
3. A silent pandemic: Industrial chemicals are impairing the brain development of children worldwide
4. Enhancing activity of marijuana-like chemicals in brain helps treat
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Crickets finicky mating behavior boosts biodiversity
7. Genome study of beneficial microbe may help boost plant health
8. Lance Armstrong through a physiological lens: hard training boosts muscle power 8%
9. Discovery of T-cell traffic control boosts new drug promise
10. New plant DNA libraries provides massive boost to worlds plant researchers
11. Good news for the medical marijuana movement: pot proliferates brain cells and boosts mood
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2019)... ... March 13, 2019 , ... Leak Detection Associates , ... and Medical Device Industries, is excited to announce that it will be returning to ... and the newly installed and highly experienced management team immediately marked Interphex ...
(Date:3/9/2019)... ... March 07, 2019 , ... ... disease diagnostics and automation – is pleased to announce the launch of the ... giving customers access to lot-specific information, including pattern images for AESQC quality controls. ...
(Date:3/9/2019)... Columbia (PRWEB) , ... March 07, 2019 , ... ... in manufacturing neurological and cellular stress research tools today announced the publication of ... for Parkinson’s Disease treatment. The antibody, still at a pre-clinical stage of development, ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... ... will review strategies for data management in modular and adaptive clinical trials. , Participants will:, ... 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... reducing risk and impact on trial success, trial teams, and trial execution , ...
(Date:3/14/2019)... ... 2019 , ... EyeCRO LLC has been awarded full accreditation ... Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State University, and ... to receive this prestigious endorsement. The award letter from AAALAC International stated: ...
(Date:3/14/2019)... , ... March 13, 2019 , ... ... 2019 ISPE Europe Biotechnology Conference , taking place in Brussels, Belgium on ... best practices, technical and operational solutions, and innovative approaches. , “Biopharmaceuticals have ...
(Date:3/11/2019)... SANTA BARBARA, Calif. (PRWEB) , ... March 11, 2019 , ... ... a superior solution for enterprise content and information management with built in GxP compliance ... solution to Generis customers to manage GxP validation and continuous compliance for ...
Breaking Biology Technology: